20,500 Shares in Indivior PLC $INDV Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,500 shares of the company’s stock, valued at approximately $494,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in INDV. CWM LLC acquired a new position in shares of Indivior in the 3rd quarter valued at $25,000. Raymond James Financial Inc. acquired a new position in Indivior in the 2nd quarter worth about $26,000. Amalgamated Bank purchased a new position in Indivior during the second quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the period. Finally, CTC Alternative Strategies Ltd. purchased a new stake in shares of Indivior in the first quarter valued at approximately $96,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on INDV. Piper Sandler reissued an “overweight” rating and issued a $41.00 price target (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Northland Securities set a $40.00 price target on shares of Indivior in a research report on Friday, October 31st. Craig Hallum reiterated a “buy” rating and issued a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. Morgan Stanley reissued an “overweight” rating and set a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Indivior presently has a consensus rating of “Buy” and an average target price of $32.71.

Indivior Stock Performance

Shares of Indivior stock opened at $36.25 on Tuesday. The business’s 50 day moving average price is $33.47 and its 200 day moving average price is $25.43. The company has a market cap of $4.53 billion, a price-to-earnings ratio of 39.40 and a beta of 0.75. Indivior PLC has a one year low of $7.62 and a one year high of $38.00.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The company had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. On average, analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.